|
業務類別
|
Biotechnology |
|
業務概覽
|
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases. |
| 公司地址
| 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103 |
| 電話號碼
| +1 267 866-0311 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.passagebio.com |
| 員工數量
| 60 |
| Ms. Kathleen Borthwick |
Chief Financial Officer and Principal Accounting Officer |
美元 420.69K |
03/03/2026 |
| Dr. William Chou, M.D. |
Director, President and Chief Executive Officer |
美元 638.46K |
03/03/2026 |
| Mr. Edgar B. Cale |
General Counsel and Corporate Secretary |
美元 436.75K |
16/04/2025 |
|
|
| Dr. William Chou, M.D. |
Director, President and Chief Executive Officer |
03/03/2026 |
| Dr. Dolan Sondhi, PhD |
Independent Director |
03/03/2026 |
| Dr. Maxine Gowen,PhD |
Chairwoman of the Board |
03/03/2026 |
| Dr. Derrell D. Porter, M.D. |
Independent Director |
03/03/2026 |
| Mr. Sandip S. Kapadia, C.P.A.,M.B.A. |
Independent Director |
03/03/2026 |
| Dr. Athena Countouriotis, M.D. |
Independent Director |
03/03/2026 |
| Mr. Thomas R. Kassberg |
Independent Director |
03/03/2026 |
|
|
|
|
